A compound represented by the General formula (I), a pharmacologically acceptable salt thereof, or a solvate of the compound or the salt can exert its effect more effectively on undifferentiated gastric cancer, and can also exerts its effect more effectively on a living body having at least one member selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2.
